ID
45794
Descripción
Principal Investigator: David Hafler, Yale School of Medicine, New Haven, CT, USA MeSH: Glioblastoma,Programmed Cell Death 1 Receptor https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001079 PD-1 is an important immune checkpoint inhibitor that shows great promise in the clinic, particularly for melanoma and lung cancers. Since PD-1 is also expressed on infiltrating CD4+ Treg and Teffector cells in glioblastoma, we sought to better understand the role of PD-1 on these infiltrating CD4+ Treg and Teffector cells. To this end, we performed functional and transcriptional profiling using CD4+ Treg and Teffector cells isolated from healthy donors and glioblastoma patients (from both tumors and blood).
Link
Palabras clave
Versiones (1)
- 23/06/23 23/06/23 - Chiara Middel
Titular de derechos de autor
David Hafler, Yale School of Medicine, New Haven, CT, USA
Subido en
23 giugno 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001079 PD-1+ and PD-1- CD4+ Teff and Treg cells in Glioblastoma and Health
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
- Subject ID, sample ID, and sample use of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
- Sample ID, MGMT methylation, sorted as PD1pos or PD1- or total, sample obtained from tumor or blood, and tumor stage of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
- Subject ID, sample ID, and sample use of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
- Sample ID, MGMT methylation, sorted as PD1pos or PD1- or total, sample obtained from tumor or blood, and tumor stage of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
C0680251 (UMLS CUI [1,2])
C0229664 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,3])
C1516698 (UMLS CUI [1,4])
C0006118 (UMLS CUI [1,5])
C0543467 (UMLS CUI [1,6])
C1292533 (UMLS CUI [2,1])
C0229664 (UMLS CUI [2,2])
C0370003 (UMLS CUI [2,3])
C1516698 (UMLS CUI [2,4])
C1708335 (UMLS CUI [2,5])